Mesothelin Antibodies And Methods For Eliciting Potent Antitumor Activity Read more about Mesothelin Antibodies And Methods For Eliciting Potent Antitumor Activity US Application 61/706,396Filed on 2012-09-27
CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES Read more about CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES US Application 61/698,227Filed on 2012-09-07
T Cells Receptors Recognizing MHC Class II-Restricted Mage-A3 Read more about T Cells Receptors Recognizing MHC Class II-Restricted Mage-A3 US Application 61/701,056Filed on 2012-09-14
A Method For The Treatment Of Obesity Read more about A Method For The Treatment Of Obesity US Application 61/368,462Filed on 2010-07-28
COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING TEMS Read more about COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING TEMS US Application 61/496,737Filed on 2011-06-14
Mesothelin Domain-Specific Monoclonal Antibodies And Use Thereof Read more about Mesothelin Domain-Specific Monoclonal Antibodies And Use Thereof US Application 61/691,719Filed on 2012-08-21
Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP) Read more about Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP) US Application 61/698,113Filed on 2012-09-07
THERAPEUTIC RNA SWITCHES COMPOSITIONS AND METHODS OF USE Read more about THERAPEUTIC RNA SWITCHES COMPOSITIONS AND METHODS OF USE US Application 61/678,434Filed on 2012-08-01
Nitric Oxide-Releasing Diazeniumdiolated Polyvinylpyrrolidone-Based Polymers, And Compositions, Medical Devices, And Uses Thereof Read more about Nitric Oxide-Releasing Diazeniumdiolated Polyvinylpyrrolidone-Based Polymers, And Compositions, Medical Devices, And Uses Thereof US Application 61/672,486Filed on 2012-07-17
Programmed Death Ligand-1 (PDL1)-transduced K562 Cells Convert Human Th1 Cells Into Regulatory T Cells Read more about Programmed Death Ligand-1 (PDL1)-transduced K562 Cells Convert Human Th1 Cells Into Regulatory T Cells US Application 61/564,174Filed on 2011-11-23